Anavex Life SciencesAVXL
About: Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.
Employees: 2
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
65% more call options, than puts
Call options by funds: $14.7M | Put options by funds: $8.92M
60% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 25
32% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 44
8% more funds holding
Funds holding: 168 [Q4 2024] → 182 (+14) [Q1 2025]
2.1% more ownership
Funds ownership: 34.84% [Q4 2024] → 36.93% (+2.1%) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]
15% less capital invested
Capital invested by funds: $316M [Q4 2024] → $270M (-$46.6M) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for AVXL.
Financial journalist opinion









